Amrutanjan Health Care , a leading player in the Indian healthcare sector, has reported a solid performance for the second quarter. The company's financial results showcase steady growth and strategic initiatives across its product portfolio.

Financial Highlights

Amrutanjan Health Care posted a 7.08% year-on-year increase in revenue from operations, reaching Rs. 117.70 crores in Q2 compared to Rs. 109.92 crores in the same quarter of the previous year. The company's profitability also saw significant improvements:

• Profit before tax (PBT) grew by 20.51% to Rs. 19.21 crores
• Profit after tax (PAT) increased by 14.23% to Rs. 15.94 crores

For the first half (H1), the company reported:

• Net sales of Rs. 211.75 crores, representing a 9.35% growth
• PBT of Rs. 30.51 crores, showing a substantial increase of 36.88%

Segment Performance

The pain management segment emerged as a key driver of growth for Amrutanjan Health Care:

• Overall pain category grew by 16%
• Body pain category achieved 21% growth

Standout products in the pain management segment included:

• Maha Strong: 31% growth
• Back Pain Roll On: 26% growth
• Head Roll On: 42% growth

Other Business Segments

1. OTC Segment: Generated Rs. 112.80 crores in Q2
2. Beverages Segment: Recorded Rs. 4.29 crores, marking a 26.55% growth
3. Comfy Brand (Women's Hygiene): Sales remained flat at Rs. 32.78 crores due to changes in quantity purchase scheme accounting

Strategic Initiatives

Amrutanjan Health Care has outlined several strategic moves to drive future growth:

1. Product Expansion: Plans to launch premium sanitary pads, targeting the urban and upmarket consumer segment
2. Brand Revival: Reviving the JIFFY analgesic brand with the introduction of a Diclofenac topical range
3. Manufacturing Capacity: A new sanitary napkin plant is expected to be commissioned by late Q4, which should enhance the Comfy brand's profitability and strategic supply

Management Commentary

The company's management highlighted several key points:

1. Implementation of the new GST law in late September impacted quarter-end billing, resulting in some softness in reported top-line figures
2. Efforts to increase chemist channel reach by 100,000 outlets by year-end are showing positive initial results, particularly in P2 markets
3. The company demonstrated operating leverage with profit growth outpacing revenue growth
4. Core strategies include:
   • Market penetration of brand Amrutanjan in P1 markets
   • Market development in P2 markets
   • Product development focus on roll-on formats and newer pain relief products
   • Increasing Comfy brand reach from 0.5 million to 1 million outlets over the next three years
   • Driving digital maturity through SAP, sales force automation, and other integrated applications

Conclusion

Amrutanjan Health Care's Q2 results reflect the company's strong position in the pain management segment and its strategic focus on expanding its product portfolio and market reach. With planned launches in the premium sanitary pad segment and the revival of its JIFFY brand, the company appears well-positioned for continued growth in the coming quarters.

Investors and market watchers will likely keep a close eye on the commissioning of the new sanitary napkin plant and the performance of the company's strategic initiatives in driving future growth and profitability.

Amrutanjan Health Care Limited (AHCL) has announced the record date for its first interim dividend for the financial year 2025-26. This development comes as part of the company's recent board meeting decisions, which also included the approval of unaudited financial results for the quarter and half-year ended September 30, 2025.

Key Details of the Dividend Announcement

The company has fixed November 18, 2025, as the record date for the payment of the first interim dividend. Shareholders whose names appear in the register of members and as beneficial owners in the records of National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL) on the record date will be eligible for the dividend.

Board Meeting Outcomes

The Board of Directors of Amrutanjan Health Care Limited convened on November 10, 2025, and made several key decisions:

1. Approved the unaudited financial results for Q2 and H1 of FY 2025-26
2. Declared the first interim dividend of Re. 1/- per share
3. The board meeting commenced at 12:00 PM and concluded at 4:30 PM

Financial Performance Highlights

The company's financial results for the quarter ended September 30, 2025, showcase its performance:

The company has shown growth in both revenue and profitability compared to the same quarter in the previous fiscal year.

Compliance and Disclosure

In compliance with regulatory requirements, Amrutanjan Health Care Limited has informed both the National Stock Exchange of India Limited (NSE) and BSE Limited about these decisions. The company adheres to the regulations set forth by the Securities and Exchange Board of India (SEBI) Listing Obligations and Disclosure Requirements.

Investors and shareholders are advised to take note of the record date to ensure their eligibility for receiving the interim dividend. As always, it is recommended that investors consult with their financial advisors before making any investment decisions based on this information.